Form 4: MAIA Biotechnology Director Buys 10,000 Shares

MAIA Biotechnology Director Cristian Luput purchased 10,000 shares of common stock at $0.9785 per share, increasing his beneficial ownership.

Summary

• Cristian Luput, a Director of MAIA Biotechnology, Inc. (MAIA), reported the acquisition of 10,000 shares of common stock.
• The transaction occurred on November 25, 2025, at a price of $0.9785 per share.
• This purchase was made pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged trading strategy.
• Following this transaction, Cristian Luput beneficially owns a total of 399,483 shares of MAIA Biotechnology common stock.

Sentiment

Score: 8

Explanation: The insider purchase by a director is a strong positive signal, indicating confidence in the company's valuation and future performance.

Positives

• Director Cristian Luput purchased 10,000 shares of MAIA Biotechnology common stock, signaling confidence in the company's future.
• The purchase was made at $0.9785 per share, indicating management's belief in the stock's value at this price point.
• The transaction increases the director's beneficial ownership to 399,483 shares, further aligning management's interests with those of shareholders.

Future Outlook

NA

Industry Context

NA

Corporate Governance

Related Party Transactions

• Director Cristian Luput, a related party, purchased 10,000 shares of MAIA Biotechnology common stock from the open market.

Stakeholder Impact

• Shareholders: Increased confidence due to insider buying, potentially signaling positive future performance and aligning management interests.
• Management: Director's increased stake further aligns personal financial interests with the long-term success and value creation of the company.

Key Dates

Recommendation

The purchase of 10,000 shares by Director Cristian Luput, especially under a Rule 10b5-1 plan, signals strong insider confidence in MAIA Biotechnology's future prospects and current valuation. This direct investment by a key executive aligns their interests with shareholders and often precedes positive company developments, making it a compelling 'buy' signal for investors.

Keywords

MAIA Biotechnology, MAIA, insider trading, Form 4, director purchase, common stock, equity acquisition, Rule 10b5-1